

---

# Guidance for Industry

## Drug Product

**Chemistry, Manufacturing, and Controls Information**

### ***DRAFT GUIDANCE***

**This guidance document is being distributed for comment purposes only.**

Comments and suggestions regarding this draft document should be submitted within 150 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit comments to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (CDER) Upinder Atwal 301-827-5848 or (CBER) Christopher Joneckis 301-435-5681.

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biologics Evaluation and Research (CBER)**

**January 2003  
CMC**

# Guidance for Industry

## Drug Product

### Chemistry, Manufacturing, and Controls Information

*Additional copies are available from:*

*Office of Training and Communication  
Division of Drug Information, HFD-240  
Center for Drug Evaluation and Research  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857  
(Tel) 301-827-4573  
<http://www.fda.gov/cder/guidance/index.htm>*

*and/or*

*Office of Communication, Training and  
Manufacturers Assistance, HFM-40  
Center for Biologics Evaluation and Research*

*Food and Drug Administration  
1401 Rockville Pike, Rockville, MD 20852-1448  
<http://www.fda.gov/cber/guidelines.htm>.  
(Tel) Voice Information System at 800-835-4709 or 301-827-1800*

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biologics Evaluation and Research (CBER)**

**January 2003  
CMC**

## TABLE OF CONTENTS<sup>1</sup>

<b>I. INTRODUCTION</b>	<b>1</b>
<b>II. BACKGROUND</b>	<b>2</b>
<b>A. The Common Technical Document — Quality (CTD-Q) Format</b>	<b>2</b>
1. <i>Format of Drug Product Information in Multiple Related Applications</i>	3
2. <i>Format of Drug Product Information for Multiple Product Presentations and/or Manufacturing Schemes in One Application</i>	3
<b>B. Content Information Included in an Application</b>	<b>4</b>
<b>C. Additional Guidance</b>	<b>5</b>
<b>D. Drug Master Files</b>	<b>6</b>
<b>E. Environmental Assessments</b>	<b>6</b>
<b>III. DESCRIPTION AND COMPOSITION OF THE DRUG PRODUCT (P.1)</b>	<b>6</b>
<b>A. Description of Dosage Form</b>	<b>6</b>
<b>B. Container Closure System</b>	<b>7</b>
<b>C. Composition Statement</b>	<b>7</b>
<b>IV. PHARMACEUTICAL DEVELOPMENT (P.2)</b>	<b>10</b>
<b>A. Components of the Drug Product (P.2.1)</b>	<b>11</b>
1. <i>Drug Substance (P.2.1.1)</i>	11
2. <i>Excipients (P.2.1.2)</i>	12
<b>B. Drug Product (P.2.2)</b>	<b>13</b>
1. <i>Formulation Development (P.2.2.1)</i>	13
2. <i>Overages (P.2.2.2)</i>	14
3. <i>Physicochemical and Biological Properties (P.2.2.3)</i>	14
<b>C. Manufacturing Process Development (P.2.3)</b>	<b>15</b>
<b>D. Container Closure System (P.2.4)</b>	<b>16</b>
<b>E. Microbiological Attributes (P.2.5)</b>	<b>16</b>
<b>F. Compatibility (P.2.6)</b>	<b>17</b>
<b>V. MANUFACTURE (P.3)</b>	<b>18</b>
<b>A. Manufacturer(s) (P.3.1)</b>	<b>18</b>
<b>B. Batch Formula (P.3.2)</b>	<b>19</b>
<b>C. Description of Manufacturing Process and Process Controls (P.3.3)</b>	<b>21</b>
1. <i>Flow Diagram</i>	21
2. <i>Description of Manufacturing Process and Process Controls</i>	22

<sup>1</sup> Alphanumeric designations in parentheses that follow headings show where information should be placed in applications that are submitted in Common Technical Document (CTD) format.

3. <i>Reprocessing and Reworking</i> .....	24
<b>D. Controls of Critical Steps and Intermediates (P.3.4)</b> .....	<b>25</b>
<b>E. Process Validation and/or Evaluation (P.3.5)</b> .....	<b>26</b>
<b>VI. CONTROL OF EXCIPIENTS (P.4)</b> .....	<b>27</b>
<b>A. Specifications (P.4.1)</b> .....	<b>28</b>
<b>B. Analytical Procedures (P.4.2)</b> .....	<b>29</b>
<b>C. Validation of Analytical Procedures (P.4.3)</b> .....	<b>29</b>
<b>D. Justification of Specifications (P.4.4)</b> .....	<b>30</b>
<b>E. Excipients of Human or Animal Origin (P.4.5)</b> .....	<b>31</b>
<b>F. Novel Excipients (P.4.6)</b> .....	<b>31</b>
<b>VII. CONTROL OF DRUG PRODUCT (P.5)</b> .....	<b>31</b>
<b>A. Specification(s) (P.5.1)</b> .....	<b>31</b>
<b>B. Analytical Procedures (P.5.2)</b> .....	<b>35</b>
<b>C. Validation of Analytical Procedures (P.5.3)</b> .....	<b>36</b>
<b>D. Batch Analyses (P.5.4)</b> .....	<b>36</b>
1. <i>Batch Analysis Reports</i> .....	37
2. <i>Collated Batch Analyses Data</i> .....	37
<b>E. Characterization of Impurities (P.5.5)</b> .....	<b>38</b>
1. <i>List of Expected Impurities</i> .....	38
2. <i>Identification of Impurities</i> .....	38
<b>F. Justification of Specification(s) (P.5.6)</b> .....	<b>40</b>
<b>VIII. REFERENCE STANDARDS OR MATERIALS (P.6)</b> .....	<b>42</b>
<b>IX. CONTAINER CLOSURE SYSTEM (P.7)</b> .....	<b>43</b>
<b>X. STABILITY (P.8)</b> .....	<b>44</b>
<b>A. Stability Summary and Conclusion (P.8.1)</b> .....	<b>44</b>
<b>B. Postapproval Stability Protocol and Stability Commitment (P.8.2)</b> .....	<b>44</b>
<b>C. Stability Data (P.8.3)</b> .....	<b>44</b>
1. <i>Formal Stability Studies</i> .....	44
2. <i>Supporting Stability Studies</i> .....	45
3. <i>Stress Studies</i> .....	45
<b>XI. APPENDICES (A)</b> .....	<b>46</b>
<b>A. Facilities and Equipment (A.1)</b> .....	<b>46</b>
<b>B. Adventitious Agents Safety Evaluation (A.2)</b> .....	<b>47</b>
1. <i>Nonviral Adventitious Agents</i> .....	48
2. <i>Viral Adventitious Agents</i> .....	48
<b>C. Excipients (A.3)</b> .....	<b>49</b>
<b>XII. REGIONAL INFORMATION (R)</b> .....	<b>50</b>

<b>A. Executed Production Records (R.1.P)</b> .....	<b>50</b>
1. <i>Executed Production Records</i> .....	50
2. <i>Information on Components</i> .....	50
<b>B. Comparability Protocols (R.2.P)</b> .....	<b>51</b>
<b>C. Methods Validation Package (R.3.P)</b> .....	<b>51</b>
<b>XIII. LITERATURE REFERENCES (3.3)</b> .....	<b>51</b>
<b>ATTACHMENT 1</b> .....	<b>52</b>
<b>GLOSSARY</b> .....	<b>58</b>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.